Business Description
Purple Biotech Ltd
ISIN : US74638P2083
Share Class Description:
PPBT: ADRTotal Employee Number:
10Compare
Compare
Traded in other countries / regions
PPBT.IsraelPPBT.USA1YI0.Germany IPO Date
2015-11-20Description
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 34.95 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 38.7 | |||||
3-Year EPS without NRI Growth Rate | 85.4 | |||||
3-Year FCF Growth Rate | 60.6 | |||||
3-Year Book Growth Rate | -72.9 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.27 | |||||
9-Day RSI | 26.96 | |||||
14-Day RSI | 28.29 | |||||
3-1 Month Momentum % | -27.32 | |||||
6-1 Month Momentum % | -58.91 | |||||
12-1 Month Momentum % | -87.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.48 | |||||
Quick Ratio | 1.48 | |||||
Cash Ratio | 1.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -115.9 | |||||
Shareholder Yield % | -46.55 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -111.33 | |||||
ROA % | -92.25 | |||||
ROIC % | -35.1 | |||||
3-Year ROIIC % | -163.73 | |||||
ROC (Joel Greenblatt) % | -8524.83 | |||||
ROCE % | -110.76 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.67 | |||||
EV-to-Forward-Revenue | 1.7 | |||||
EV-to-FCF | 0.01 | |||||
FCF Yield % | -108.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PPBT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Purple Biotech Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -386 | ||
| Beta | -0.2372 | ||
| 3-Year Sharpe Ratio | -1.21 | ||
| 3-Year Sortino Ratio | -1.38 | ||
| Volatility % | 87.54 | ||
| 14-Day RSI | 28.29 | ||
| 14-Day ATR ($) | 0.260091 | ||
| 20-Day SMA ($) | 2.268005 | ||
| 12-1 Month Momentum % | -87.55 | ||
| 52-Week Range ($) | 1.42 - 29 | ||
| Shares Outstanding (Mil) | 0.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Purple Biotech Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Purple Biotech Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 137 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 38 days | ||
| General meeting for 2026 | 2026-06-26 16:30 | 1.75 (+0.57%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 3.69 (-6.95%) | ||
| Annual report for 2025 | 2026-03-19 | 3.81 (-4.75%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-13 | 3.84 (-4.00%) | ||
| 0.1:1 Stock Split | 2026-03-02 | 4.42 (-7.83%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 7.40 (-3.87%) | ||
| Second quarter earnings results for 2025 | 2025-08-06 | 22.60 (+3.43%) | ||
| First quarter earnings results for 2025 | 2025-05-21 | 24.10 (+4.78%) |
Show
Entries
Purple Biotech Ltd Frequently Asked Questions
What is Purple Biotech Ltd(PPBT)'s stock price today?
The current price of PPBT is $1.68. The 52 week high of PPBT is $29.00 and 52 week low is $1.42.
When is next earnings date of Purple Biotech Ltd(PPBT)?
The next earnings date of Purple Biotech Ltd(PPBT) is 2026-08-06 Est..
Does Purple Biotech Ltd(PPBT) pay dividends? If so, how much?
Purple Biotech Ltd(PPBT) does not pay dividend.
Guru Commentaries on NAS:PPBT
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research | 2018-04-13 |
Articles on Purple Biotech Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers